Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05NWF
|
|||
| Former ID |
DIB018757
|
|||
| Drug Name |
adenosine diphosphate
|
|||
| Synonyms |
Adenosine diphosphate; 58-64-0; ADP; Adenosine 5'-(trihydrogen diphosphate); adenosine pyrophosphate; adenosine 5'-pyrophosphate; ADP (nucleotide); adenosine-diphosphate; 5'-Adenylphosphoric acid; 5'-Adp; Adenosindiphosphorsaeure; Adenosine 5'-pyrophosphoric acid; Adenosine-5'-diphosphat; Adenosine 5'-diphosphoric acid; Adenosine diphosphoric acid; Ado-5'-P-P; UNII-61D2G4IYVH; H3adp; BRN 0067722; CHEBI:16761; EINECS 200-392-5; 61D2G4IYVH; CHEMBL14830
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C10H15N5O10P2
|
|||
| Canonical SMILES |
C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N
|
|||
| InChI |
1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
|||
| InChIKey |
XTWYTFMLZFPYCI-KQYNXXCUSA-N
|
|||
| CAS Number |
CAS 58-64-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3310, 583708, 583773, 583911, 583921, 583922, 584175, 584188, 584204, 584229, 584302, 584513, 584515, 584599, 584626, 584627, 584628, 584632, 584641, 584643, 585456, 585517, 585721, 585872, 793510, 819880, 819957, 820163, 820296, 820360, 820365, 820433, 820439, 820507, 820515, 820541, 820600, 821195, 821592, 821838, 821868, 822043, 822090, 822091, 822116, 822129, 822159, 822163, 822165, 822167
|
|||
| ChEBI ID |
CHEBI:16761
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Long transient receptor potential channel 4 (TRPM4) | Target Info | Inhibitor (gating inhibitor) | [1] |
| P2Y purinoceptor 1 (P2RY1) | Target Info | Agonist | [2] | |
| P2Y purinoceptor 12 (P2RY12) | Target Info | Agonist | [3] | |
| P2Y purinoceptor 13 (P2RY13) | Target Info | Agonist | [4] | |
| P2Y purinoceptor 6 (P2RY6) | Target Info | Agonist | [5] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Platelet activation | ||||
| Reactome | G alpha (q) signalling events | |||
| P2Y receptors | ||||
| ADP signalling through P2Y purinoceptor 1 | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5. | |||
| REF 2 | Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. | |||
| REF 3 | P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. | |||
| REF 4 | Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. | |||
| REF 5 | Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.